EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia

Xiaoyu Zhang, Donglin Yang, Aiming Pang, Sizhou Feng, Mingzhe Han, Yi He iD, Erlie Jiang iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70116 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Hematological Oncology, 2025. Verfasst von Xiaoyu Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Mitoxantrone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite allo‐HSCT being the primary curative treatment for high‐risk AML, relapse‐free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantrone Hydrochloride Liposome (Lipo‐MIT), a novel nano‐formulation with enhanced pharmacokinetic properties and demonstrated anti‐leukemic efficacy. Preclinical studies have shown that Lipo‐MIT significantly improves survival outcomes compared to conventional mitoxantrone, and our study aims to translate these findings into clinical practice. In this study, we present the results of a Lipo‐MIT as part of the conditioning regimen for high‐risk AML patients undergoing allo‐HSCT. Our findings highlight the potential of Lipo‐MIT to improve RFS, while also providing insights into patient selection and the refinement of Lipo‐MIT‐based conditioning strategies. We believe this work contributes valuable knowledge to the field and has the potential to impact clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMitoxantroneTransplantation ConditioningAdultAgedFemaleHumansMaleMiddle AgedYoung AdultLiposomes

Stichwörter der Autor:innen

ELN high‐riskacute myeloid leukemia (AML)allogeneic hematopoietic stem cell transplantation (allo‐HSCT)mitoxantrone hydrochloride liposome

Substanzen

LiposomesMitoxantrone

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, China.

ORCID-Profile: Yi He, Erlie Jiang

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Yang, D., Pang, A., Feng, S., Han, M., He, Y., & Jiang, E. (2025). The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia. Hematological Oncology. https://doi.org/10.1002/hon.70116

Vancouver

Zhang X, Yang D, Pang A, Feng S, Han M, He Y, et al. The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia. Hematological Oncology. 2025. doi:10.1002/hon.70116

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiaoyu and Yang, Donglin and Pang, Aiming and Feng, Sizhou and Han, Mingzhe and He, Yi and Jiang, Erlie},
  title = {The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70116}
}
Kostenlos starten →